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Patients from higher rank hospitals received more TCHM treatment (OR=1.12, 
P<0.01) than their counter parts. Use of TCHM is also higher (OR=2.49, P<0.01) in 
eastern(developed area) than in mid-western(developing area). CONCLUSIONS: 
 F Factors associate with utilization of TCHM include both patient demand and 
TCHM service supply. The study calls for further investigations on availability of 
TCHM and practitioners in different geographic locations. It is also worthwhile to 
identify comparative advantages of TCHM to western medicine in treating 
different conditions in order to fulfill its roles with the current Chinese health 
care reform.  
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OBJECTIVES: China’s evolving health care market demands advanced oncology 
agents for its patients; however, the formulary (drug list) access system for these 
drugs is complex to navigate. This research aims to identify those critical factors 
that support formulary access and utilization for “advanced oncology agents 
(AOA)” in China. METHODS: Telephonic interviews were conducted with twelve 
formulary decision makers and influencers (FDM) from three large provinces in 
China, Beijing, Shanghai, and Guangzhou. FDM were identified and selected for 
their role in access and reimbursement decisions in their local health care 
systems, and included pharmacoeconomists, insurance officers, directors of 
hospital pharmacy, and key opinion leading oncologists (KOL). Each FDM was 
interviewed in their native language for 60 to 90 minutes. Responses were 
tabulated and analyzed. RESULTS: Interviews revealed that none of the AOA are 
covered in the National Reimbursement Drug List (NRDL), however, some are 
reimbursed at the provincial level on the Provincial Reimbursement Drug List 
(PRDL). The provinces that include AOA on their PRDL share common attributes, 
most notably, the local government has significant decision-making power, and 
its medical insurance fund has a relatively high balance. Factors that influence 
AOA utilization in China include physician willingness to prescribe, support by 
regional KOL, patient affordability, listing on hospital and provincial drug lists, 
and hospital budget. There are locally-funded insurance programs, and 
manufacturer-funded patient-assistance programs, available to help reduce the 
patient-burden of treatment for chronic and high-cost diseases. KOL are critical 
to the decisions to include AOA in these programs. CONCLUSIONS: The critical 
success factors that support access and utilization of AOA in China include 
advocacy for drug listing by regional KOL, achieving listing on local hospital drug 
lists, and inclusion of drugs in local insurance- and manufacturer-funded patient 
programs.  
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OBJECTIVES: Melanoma is a skin cancer originated in melanocytes and is 
predominant in white adults. Skin cancer is the most common cancer in Brazil 
corresponding to 25% of all malignant tumors registered. Melanoma accounts for 
only 4% of the malignant neoplasms of the skin, but it has very high lethality. 
The objective of this research is to describe resource utilization and costs 
associated with melanoma treatment in Brazil and across the country’s regions; 
to compare chemotherapy and surgery in relation to patients’ characteristics and 
average costs. METHODS: A sample of 3 million Brazilian supplementary health 
care system patients was accessed in a electronic administrative database 
(BI.2iM) to identify resource utilization in 2011. The search was retrospective and 
conducted using the melanoma ICD 10 code (C43) as driver. Cost information is 
in Brazilian reais (US$1.00 = R$ 2.00) RESULTS: 94 patients were identified by the 
melanoma IC10 code in 2011. These patients sample consumed R$ 9,1 million 
(mean annual cost of R$ 96,268) with 81% of these costs referred to surgical 
procedures, radiotherapy 12%, chemotherapy 1% and others expendures 6%. 
Projecting the number of cases found in BI.2iM in the population covered by 
health plans in Brazil it would be expected around 1,504 cases to be treated per 
year at a potential cost of 144, 7 million. CONCLUSIONS: This data suggest that 
surgical procedures are the main cost related with the melanoma treatment in 
the Brazilian supplementary health care system. Understanding treatment 
preferences and patterns is mandatory to analyze new treatments cost-
effectiveness ratio.  
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OBJECTIVES: With the approval of imatinib (ima), systemic therapy (ST) for 
gastrointestinal stromal tumors (GIST) has changed substantially. This study 
evaluated treatment patterns and costs of patients receiving first-line (1LT) ima 
for GIST. METHODS: A retrospective study spanning 1/1/03-9/30/11 was 
conducted utilizing pharmacy/medical claims data from a large health plan. 
Patients with GIST-related ICD9 codes who initiated ima were eligible. Patients 
were excluded if they received any chemotherapy prior to date of first diagnosis 
or ima. Adjuvant patients (APs) were defined as receiving GIST-related surgery 
prior to ima. Patients were followed from diagnosis to end of the study period or 
loss of continuous eligibility to describe post-ima ST and evaluate corresponding 
GIST-related average monthly costs. RESULTS: One hundred patients (45 APs) 
with average follow-up time of 1113 days (range 385–2,901 days) met all inclusion 
criteria. The average time between first diagnosis and initiation of ima therapy 
was 207 days for AP versus 140 days for non-adjuvant patients (NAPs). Average 
monthly costs prior to ima therapy were $7,025; APs, $11,095/month. APs 
remained on ima therapy for an average of 463 days versus 404 days for NAPs. 
Monthly therapy costs across both cohorts were $3919 (SD=$1822), almost 92% of 
total monthly costs. Twenty-one patients moved onto post-ima second-line 
therapy (2LT), with 81% (n=17) receiving sunitinib (sun). APs moving onto 
second-line therapy remained on treatment 148 days versus 256 days for NAPs. 
2LT average monthly cost: AP=$8813; NAP=$5894; over 70% related to ST. 6 of the 
21 patients received third-line therapy (3LT) (3-nilotinib, 2-sorafenib, 1-
cyclophosphamide) for an average of 48 days; treatment costs averaged 
$1774/month. CONCLUSIONS: Post-ima 2LT for GIST was dominated by sun, 
while 3LT varied among the few patients who initiated this line of care. Across 
all lines of care, therapy cost was the primary driver of cost.  
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OBJECTIVES: To investigate the effect of Medicare’s cut in chemotherapy 
reimbursement (implemented in 2004-2005) on rituximab prescription among 
Non-Hodgkin’s Lymphoma (NHL) patients and to estimate the marginal survival 
benefits of rituximab using an instrumental variable (IV) approach. METHODS: 
Using the Surveillance, Epidemiology and End Results (SEER)-Medicare linked 
database, we studied patients 66 years or older diagnosed with first primary NHL 
from 2002-2007 (N=19,424). Logistic regression was used to assess the impact of 
Medicare reimbursement cut on first course rituximab prescription, after 
controlling for clinical and non-clinical factors. Two stage least square 
regressions using Medicare reimbursement policy as IV were used to estimate 
whether the changes in the rituximab prescription rates could lead to one and 
three years of survival benefit. RESULTS: In the post-policy period (2004-2008) 
the likelihood of rituximab prescriptions increased as compared to the pre-policy 
period (AOR of 1.52 in 2004, AOR of 1.79 in 2005 and after, respectively). Using IV 
approach, we found that the first course of rituximab prescription among NHL 
patients significantly improved one- and three-year survival (effectiveness 
estimate=0.37 for one-year survival, effectiveness estimate=0.44 for three-year 
survival respectively). CONCLUSIONS: Rituximab prescriptions increased in 
response to the Medicare’s reimbursement cut. Substantial rituximab survival 
benefits were observed among marginal NHL patients whose treatment choices 
were affected by the policy change.  
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OBJECTIVES: The Medicare Prescription Drug, Improvement and Modernization 
Act of 2003 (MMA) changed reimbursement of outpatient drugs reimbursed 
under Medicare Part B from 95% of average wholesale price to 106% of the 
average sales price as a cost saving measure. Shortly thereafter many 
commercial payers followed suit. This analysis examines the impact of the 
change in the reimbursement schedules on actual payments provided to 
physicians for administrations of 5 high cost Part B reimbursed oncology drugs. 
METHODS: Using the MarketScan Research Databases©, claims for 
administrations of pemetrexed, bevacizumab, trastuzumab, rituximab, 
docetaxel, and zoledronic acid were identified from January 1, 2004 through 
December 31, 2011 among cancer patients with non-capitated commercial or 
employer-sponsored supplemental Medicare insurance. Claims were excluded 
from the payment analysis if the reimbursed amount was less than $100 to omit 
use for other indications, such as the use of bevacizumab for treatment of 
macular degeneration. Median reimbursed amounts, encompassing both plan 
and patient paid amounts, were reported by year, after adjusting to 2011 dollars 
using the consumer price index. Compound annual growth rates (CAGRs) 
between 2004 and 2011 were computed to assess the change in reimbursements 
over time. RESULTS: A total of 1.98M Commercial and 839k Medicare claims were 
analyzed. Negative CAGRs between 2004-2011 were observed in only two of the 
therapies: pemetrexed (-11% CAGR in Commercial population) and zoledronic 
acid (-2 % to -3% in the Medicare and Commercial population, respectively). The 
remaining oncology Part B therapies exhibited CAGRs of 1-5%, with the exception 
of trastuzumab which had 11-13% growth. CONCLUSIONS: The amount 
reimbursed for several key oncology therapies administered in providers offices 
did not shift dramatically downward after the implementation of MMA. Further 
research will examine shifts in dosage levels, frequency, and location of 
administrations (office vs. hospital) to determine the drivers of the upward shift 
in average reimbursed amount per claim.  
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The pan-Canadian Oncology Drug Review (pCODR) was established in 2010  
to provide provinces and territories with recommendations on reimbursement 
for cancer drugs. OBJECTIVES: The objective of this study was to analyze  
the recommendations made by pCODR in its first year of operation and identify 
trends. METHODS: Clinical and economic guidance reports and 
recommendations, publically accessible at www.pcodr.ca were reviewed. 
RESULTS: Since pCODR began accepting submissions in 2011, ten of twenty 
applications have received recommendations. Of the seven positive 
recommendations, one suggested a more limited patient population than  
the one requested (Votrient - metastatic renal cell carcinoma). In six  
cases (Afinitor, Halaven, Jakavi, Sutent, Yervoy, Zelboraf), positive 
recommendations for the requested population were made, conditional on cost-
effectiveness being improved to an “acceptable” level; thus encouraging 
provincial negotiations on rebates. Three negative recommendations were made 
due to: a) limitations in evidence from open-label, phase two trials (Xalkori - 
advanced non-small cell lung cancer); b) modest progression-free survival, lack 
of statistically significant overall survival, lack of quality of life data and  
poor cost-effectiveness (Votrient - soft tissue sarcoma), and; c) unclear clinical 
benefit and an unacceptable cost-effectiveness model (Treanda - relapsed/ 
refractory chronic lymphocytic leukemia). In some cases the economic reviews 
by pCODR included modifications (i.e., shortening time horizons  
and modifying dose) to the submitted model. CONCLUSIONS: The 
recommendations from pCODR offer new insights into the future of oncology 
drug reimbursement in Canada. The probability of a positive recommendation 
appears to increase with randomized controlled trials, positive overall survival 
and comparators reflecting current care. Finally, the positive recommendations 
clearly support a continued provincial product listing agreement structure that 
includes rebates to lower cost-effectiveness. The new pCODR review process 
highlights the value of strong clinical data and robust cost-effectiveness 
modeling.  
 
PCN142  
COMPARISON OF CANCER THERAPY REIMBURSEMENT DECISIONS MADE IN 
CANADA TO AUSTRALIA, SWEDEN AND THE UNITED KINGDOM  
Samjoo IA1, Grima DT2 
1Cornerstone Research Group Inc., Burlington, ON, Canada, 2Cornerstone Research Group, 
Burlington, ON, Canada  
OBJECTIVES: Our aim was to compare recommendations made by the pan-
Canadian Oncology Drug Review (pCODR) one year after its launch to other 
markets. METHODS: Publically accessible recommendations were reviewed: 
Canada (pCODR; www.pcodr.ca), UK (National Institute for Health and Clinical 
Excellence (NICE), www.nice.org.uk), Sweden (Dental and Pharmaceutical 
Benefits Agency (TLV), www.tlv.se), and Australia (Pharmaceutical Benefits 
Advisory Committee (PBAC), www.pbs.gov.au). RESULTS: pCODR had four 
product reviews in common with NICE, three with TLV, and five with PBAC. 
pCODR and NICE recommendations were most consistent; both positively 
recommended Votrient, Yervoy and Zelboraf. Inconsistency was observed for 
Halaven (pCODR = positive; NICE = negative). Compared to TLV, consistent 
positive recommendations were noted for Votrient and Yervoy, while 
inconsistency was observed for Zelboraf (pCODR = positive; TLV = negative). 
pCODR and PBAC were the least consistent; Votrient (renal cell carcinoma) 
received a positive recommendation and Votrient (soft tissue sarcoma) received 
a negative recommendation from both, Afinitor, Sutent, and Yervoy received 
positive recommendations by pCODR and negative recommendations by PBAC. 
Only two therapies were reviewed by all four groups: Votrient (renal cell 
carcinoma) which received a positive recommendation by all and Yervoy which 
received a positive recommendation by all, except PBAC. CONCLUSIONS: For 
products that were reviewed by pCODR and at least one other agency, the most 
consistency was observed with NICE. Discordance in recommendations may 
reflect process differences. For example, pCODR can positively recommend a 
product with acceptable clinical value conditional on improved cost-
effectiveness. However, the degree of improvement is not reviewed with the 
manufacturer; instead it is negotiated with the provincial reimbursement bodies. 
While other agencies, such as NICE, will specify a patient access scheme with the 
manufacturer as part of the recommendation process. In addition, pCODR is the 
only oncology-specific agency in these countries.  
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OBJECTIVES: Cancer drugs are the world's highest selling category of therapeutic 
products. Due to their premium price and budget impact several new drug 
reimbursement models have been implemented worldwide by public and private 
payers. These models have potential implications for coverage and 
reimbursement of all branded products. This study reviewed recent cancer drug 
reimbursement models and developed lessons and implications for future 
products. METHODS: Reviewed cancer drug reimbursement schemes in 
developed and emerging markets. Interviewed payers and KOLs to develop 
lessons and implications for future products. RESULTS: Public and private payers 
worldwide have implemented several new models for cancer drug 
reimbursement to manage budgets and control costs. In the U.S., private payers 
are piloting single source compendia and third party protocols (eg. P4 Oncology) 
to limit off-label use of cancer drugs. In the UK, NICE has successfully negotiated 
lower price and discounts for the first few cycles of therapy. In Italy, AIFA has 
implemented registry based patient access for cancer drugs. In India, several 
manufacturers have implemented novel pricing strategy for the first few cycles 
of therapy. In Germany, IQWIG has proposed to use correlations between 
surrogate endpoints and patient relevant outcomes to determine the value of 
cancer drugs. Due to the increased cost pressure on payers, such models are 
likely to inspire novel reimbursement schemes for other branded products. 
CONCLUSIONS: Cancer drug reimbursement models are setting new benchmark 
for payers to manage access and control costs. These models have significant 
implications for other expensive branded products.  
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OBJECTIVES: Unsatisfactory cervical cancer screening cytology samples (Unsats), 
impose a high financial burden on the health care system. Unsats are important 
because they are more prevalent in women with invasive cervical cancer. The 
purpose of this study is to estimate the impact of Unsats on the cost of cervical 
cancer screening programs as well as on patient outcomes in a U.S. population of 
women. METHODS: A state-transition Markov model was used to simulate 
cervical cancer screening and follow-on treatment for a cohort of 1 million U.S. 
women (21-65 years of age). The screening algorithm used was based on current 
U.S. cervical cancer screening guidelines which call for primary cytology testing 
every 3 years for women between the ages of 21 and 65, with an HPV reflex test 
for those who have an abnormal cytology result. For women over 30, the U.S. 
guidelines recommend the option of a cytology/HPV co-test every 5 years. Other 
inputs included U.S. high-risk HPV prevalence; age-specific cervical cancer 
incidence and associated mortality; age-specific cervical cancer screening and 
treatment compliance; HPV vaccination rates; and U.S. health care resource cost 
data. RESULTS: Unsats are costly to cytology laboratories as all of the costs 
associated with reprocessing these samples must be absorbed by the labs. 
Samples for which reprocessing is unsuccessful impose a greater burden on the 
health care system in terms of the costs associated with patients returning to 
physicians’ offices for a second sample collection. Some patients who should 
return for a second collection are lost to follow-up, presenting an opportunity for 
disease progression. CONCLUSIONS: The Unsat rate associated with a cytology 
test can significantly increase the effective cost of the test. All costs need to be 
considered in order to determine the true cost of a cytology test for cervical 
cancer.  
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OBJECTIVES: For the contemporary health care, creation of patient registries is a 
crucial task; first of all they facilitate, from the evidence-based medicine 
position, the problem of introduction of new effective drugs (including biological 
drugs). The purpose of this study was to describe the first experience of creation 
a breast cancer patient registry in the Russian Federation. METHODS: As of 
24.07.2012, the Registry included 11,960 patients from 16 regions of Russia. The 
proportion of Moscow residents is 49.9%. RESULTS: It is found that only in 9.7% 
of cases included in the Registry breast cancer was detected at stage I. Most 
commonly the diagnosis was established at the following stages: IIA (27.5%), IIB 
(17.1%) and IIIA (19.9%). It is worth noting that in the regions the diagnosis of 
stage I cancer was established more frequently than in Moscow (chi-square=204, 
p<0.000). Assessment of the distribution of patients in the Registry by expression 
of estrogen and progesterone receptors (ER/PR) was performed for only 1195 
(16.7%) of cases where test results were available. Positive HER-2 status was 
found in 14.9% of patients in the Registry. In patients with stage I and stage II, a 
clear prevalence of HER-2 negative cases was found, whereas in patients with 
stage III and stage IV positive status prevailed. Hormonal anti-progesterone 
therapy was given to 1345 patients (94.7% of women with overexpression of 
estrogen and progesterone receptors). 83 patients received treatment with 
trastuzumab. This is consistent with the total number of HER-2 positive patients 
(101); the coverage is equal to 82.2% and considered sufficient. CONCLUSIONS: 
Analysis of the Registry revealed insufficient use of up-to-date immunoassays, 
including estrogens and progesterone receptors typing, it also showed that it is 
early stages of the disease when one can expect better clinical effect from the 
use of hormone therapy and biological therapy.  
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OBJECTIVES: The educational content of disease awareness raising activities 
concerning Human Papilloma Virus (HPV) vaccine that were targeted directly to 
consumers in Thailand was evaluated in terms of the pattern and quality of the 
advertised activities. METHODS: The activities targeted at Thai consumers 
during January 2006 and December 2008, via various mass media including 
television, magazines, and the internet were identified using health and HPV-
related keywords. The pattern of disease awareness raising activities was 
assessed by using content analysis method while the quality of educational 
content was appraised by two pharmacists using evidence-based publications 
and guidelines from the Cancer Institute of Thailand and medical associations 
